ACCE price target published on 22 Oct 2026, 16:00 CEST.
Price used: ₹4524 at the close on 23 Oct 2026, 12:00 CEST.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
ACCE score
57
out of 100
P/E
72.3x
forward 48.5x
1-year return
+25.2%
Dividend yield
0.82%
Torrent Pharmaceuticals Limited in four questions
Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
Overview
ACCE thesis
Torrent Pharmaceuticals makes branded and generic cardiovascular, neuropsychiatric and diabetes formulations for the Indian market, and has a growing export business in regulated and semi-regulated markets. Its edge is a dense domestic sales force and a long-established cardiac and CNS franchise that gives it prescriber access that new entrants struggle to replicate. The near-term story is the integration and scale-up of its recent acquisitions, which should lift revenue further and support margin expansion as synergies come through. Reported revenue growth of 54.8% and a 76.0% gross margin sit alongside a 21.8% operating margin, so the question for a PM is how much of that growth is organic and how quickly operating margin converges toward gross margin levels. At 73.7 trailing and 49.5 forward earnings, the stock is priced for that expansion to be delivered, which makes it a name worth a closer look on the reported numbers rather than on the multiple alone.